Available Trials
Colorectal Cancer
- Colon, RectumPhase II Pilot Study of FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal CancerPrincipal Investigator: Stacey Stein
- Colon, RectumRandomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer (SOLARIS)Principal Investigator: Christina Gomez
- Colon, RectumTemozolomide and Olaparib for O6-Methylguanine DNA Methyltransferase Promoter Hypermethylated Colorectal CancerPrincipal Investigator: Michael Cecchini
- Anus, Colon, Rectum, Small Intestine, Phase IA Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 ExpressionPrincipal Investigator: Joseph Paul Eder
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
Gastric and Esophageal
- Other Digestive OrganA Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract CarcinomaPrincipal Investigator: Stacey Stein
- Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Thyroid, Phase IA Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)Principal Investigator: Barbara Burtness
- Esophagus, Kidney, Melanoma, skin, Pancreas, Stomach, Phase I, CervixA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesPrincipal Investigator: Joseph Paul Eder
- Esophagus, Larynx, Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCAPrincipal Investigator: Aarti Bhatia
Liver Cancer
- LiverA Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)Principal Investigator: David C. Madoff
- Liver, Lung, Melanoma, skin, Other Female GenitalPhase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrial CarcinomaPrincipal Investigator: Mario Sznol
- LiverA Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)Principal Investigator: Stacey Stein
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Anus, Breast - Female, Breast - Male, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Urinary BladderAn Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic MalignanciesPrincipal Investigator: Patricia LoRusso
Pancreatic Cancer
- PancreasPhase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic AdenocarcinomaPrincipal Investigator: Kimberly L. Johung
- Esophagus, Kidney, Melanoma, skin, Pancreas, Stomach, Phase I, CervixA Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced MalignanciesPrincipal Investigator: Joseph Paul Eder
- Anus, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Pancreas, Prostate, Rectum, Small Intestine, Stomach, Thyroid, Phase I, Breast, Urinary BladderA Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsPrincipal Investigator: Joseph Kim
- Lung, PancreasA Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAPPrincipal Investigator: Frederick Wilson